Eisai
EU Regulatory Panel Rejects Eisai and Biogen’s Leqembi for Alzheimer’s Treatment
Leqembi, Alzheimer’s disease, Eisai, Biogen, European Medicines Agency, regulatory panel, approval rejection, adverse effects
European Regulators Reject Eisai and Biogen’s Alzheimer’s Drug Leqembi
Eisai, Biogen, Leqembi, Alzheimer’s disease, European Medicines Agency, drug rejection
Bristol Myers Squibb Ends Collaboration with Eisai on Antibody-Drug Conjugate Due to Portfolio Prioritization
Bristol Myers Squibb, Eisai, Antibody-Drug Conjugate, Portfolio Prioritization, Collaboration, Farletuzumab Ecteribulin